CJC-1295 + GHRP-6 Stack vs Ghrelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profileGhrelin
Endogenous 28-amino acid peptide secreted primarily by the stomach that functions as both the primary hunger signal and a potent growth hormone secretagogue. The n-octanoyl modification at Ser-3 (acylated form) is required for GHS-R1a receptor binding and GH-stimulating activity. Understanding ghrelin explains the mechanism behind the entire GHRP class of research peptides.
Full profile| CJC-1295 + GHRP-6 Stack | Ghrelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | GHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelin |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal |
| Administration | Subcutaneous injection | Intravenous (research), Subcutaneous injection |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Appetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulation |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while Ghrelin is investigational (in trials).
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; Ghrelin — Intravenous (research), Subcutaneous injection.
- Dosing units differ: CJC-1295 + GHRP-6 Stack is dosed in mcg, Ghrelin in mcg/kg — they operate at different scales.
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); Ghrelin is IV or SC bolus; endogenous levels peak pre-meal.
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
Ghrelin
Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.